Live Breaking News & Updates on Synbio Biotechnologies

Globally, there is an urgency to develop effective, low-cost therapeutic interventions for coronavirus disease 2019 (COVID-19). We previously generated the stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21). Using Syrian hamsters that model moderate to severe COVID-19 disease, we demonstrate the high efficacy of PiN-21 to prevent and treat SARS-CoV-2 infection. Intranasal delivery of PiN-21 at 0.6 mg/kg protects infected animals from weight loss and substantially reduces viral burdens in both lower and upper airways compared to control. Aerosol delivery of PiN-21 facilitates deposition throughout the respiratory tract and dose minimization to 0.2 mg/kg. Inhalation treatment quickly reverses animals’ weight loss after infection, decreases lung viral titers by 6 logs leading to drastically mitigated lung pathology, and prevents viral pneumonia. Combined with the marked stability and low production cost, this innovative therapy may provide a convenient and cos ....

United States , Sakura Finetek , Akoya Biosciences , Economic Development , Accreditation Of Laboratory Animal Care , Commonwealth Of Pennsylvania Department Community , Henryl Hillman Foundation , University Of Pittsburgh , Richard King Mellon Foundation , Vaccine Research , Association For Assessment , Laboratory Animals , National Institutes Of Health , University Of Pittsburgh Center , University Of Pittsburgh Institutional Animal Care , Public Health Services Policy On Humane Care , Regional Biocontainment Laboratory , Zymo Research , Using Syrian , Laboratory Animal , National Institutes , Animal Welfare Act , Public Health Services Policy , Humane Care , Pittsburgh Institutional Animal Care , Use Committee ,